Acute ingestion of > 150 mg/kg of salicylates may result in severe toxicity. Salicylate tablets may form stomach bezoars, prolonging absorption of the drug and toxicity. Chronic toxicity can occur after several days or more of high therapeutic doses; it is common, often undiagnosed, and often more serious than acute toxicity. Chronic toxicity is likely to occur in elderly patients L2692.
Treatment for salicylate poisoning consists of activated charcoal and alkaline diuresis with extra KCl L2692.
Unless contraindicated (eg, by altered mental status), activated charcoal is administered as soon as possible and, if bowel sounds are active and there is adequate gastrointestinal motility, may be repeated every 4 hours until charcoal appears in the stool L2692.
After volume and electrolyte abnormalities are corrected and maintained, alkaline diuresis can be used to increase urine pH, ideally to ? 8. Alkaline diuresis is advised for patients with any symptoms of poisoning and should not be delayed until salicylate levels are determined. This process is usually safe and greatly increases the rate of salicylate excretion. Because hypokalemia can interfere with alkaline diuresis, patients are often given a solution composed of 1 L of 5% D/W, 3 50-mEq ampules of NaHCO3, and 40 mEq of KCl at 1.5 to 2 times the maintenance IV fluid rate. Serum potassium levels are monitored. Due to the fact that fluid overload can lead to the occurrence of pulmonary edema, patients are monitored for respiratory findings L2692.
Drugs that increase urinary HCO3 (eg, acetazolamide) must be avoided because they worsen metabolic acidosis and decrease blood pH. Drugs that decrease respiratory drive should be avoided when possible because they may impair hyperventilation and respiratory alkalosis, decreasing blood pH L2694.
Glycol salicylate, also known as 2-hydroxyethyl salicylate, is a benzoate ester formed from the condensation of the carboxy group of salicylic acid with one of the hydroxy groups of ethylene glycol. It is found as an active ingredient and topical analgesic in patches used to provide relief for mild to moderate muscle and joint pain L2686.
This drug belongs to the salicylate group of drugs, which are used as analgesic agents for the treatment of mild to moderate pain L2691.
Glycol salicylate (GS), composed of salicylic acid (SA) and ethylene glycol, is a non-steroidal anti-inflammatory drug L2687.
This ingredient is an important component of many topical creams and sprays for the relief of aches, pains, and stiffness of the muscles, joints, and tendons L2696.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aliskiren | The risk or severity of renal failure and hypertension can be increased when Glycol salicylate is combined with Aliskiren. |
| Deferasirox | The risk or severity of gastrointestinal bleeding and peptic ulcer can be increased when Glycol salicylate is combined with Deferasirox. |
| Desmopressin | The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Glycol salicylate is combined with Desmopressin. |
| Digoxin | Glycol salicylate may decrease the excretion rate of Digoxin which could result in a higher serum level. |
| Metildigoxin | Glycol salicylate may decrease the excretion rate of Metildigoxin which could result in a higher serum level. |
| Acetyldigoxin | Glycol salicylate may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level. |
| Drospirenone | The risk or severity of hyperkalemia can be increased when Glycol salicylate is combined with Drospirenone. |
| Haloperidol | The therapeutic efficacy of Haloperidol can be increased when used in combination with Glycol salicylate. |
| Hydralazine | Glycol salicylate may decrease the antihypertensive activities of Hydralazine. |
| Lithium hydroxide | Glycol salicylate may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level. |
| Lithium citrate | Glycol salicylate may decrease the excretion rate of Lithium citrate which could result in a higher serum level. |
| Lithium carbonate | Glycol salicylate may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. |
| Methotrexate | The serum concentration of Methotrexate can be increased when it is combined with Glycol salicylate. |
| Pemetrexed | Glycol salicylate may decrease the excretion rate of Pemetrexed which could result in a higher serum level. |
| Pralatrexate | Glycol salicylate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. |
| Probenecid | Probenecid may decrease the excretion rate of Glycol salicylate which could result in a higher serum level. |
| Tenofovir disoproxil | Glycol salicylate may decrease the excretion rate of Tenofovir disoproxil which could result in a higher serum level. |
| Tenofovir alafenamide | Glycol salicylate may decrease the excretion rate of Tenofovir alafenamide which could result in a higher serum level. |
| Tenofovir | Glycol salicylate may decrease the excretion rate of Tenofovir which could result in a higher serum level. |
| Treprostinil | The risk or severity of bleeding can be increased when Treprostinil is combined with Glycol salicylate. |
| Vancomycin | Glycol salicylate may decrease the excretion rate of Vancomycin which could result in a higher serum level. |
| Alendronic acid | The risk or severity of adverse effects can be increased when Glycol salicylate is combined with Alendronic acid. |
| Lepirudin | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Lepirudin. |
| Bivalirudin | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Bivalirudin. |
| Alteplase | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Alteplase. |
| Urokinase | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Urokinase. |
| Reteplase | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Reteplase. |
| Anistreplase | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Anistreplase. |
| Tenecteplase | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Tenecteplase. |
| Abciximab | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Abciximab. |
| Drotrecogin alfa | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Drotrecogin alfa. |
| Streptokinase | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Streptokinase. |
| Dicoumarol | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Dicoumarol. |
| Argatroban | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Argatroban. |
| Ardeparin | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Ardeparin. |
| Phenindione | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Phenindione. |
| Fondaparinux | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Fondaparinux. |
| Warfarin | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Warfarin. |
| Pentosan polysulfate | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Pentosan polysulfate. |
| Phenprocoumon | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Phenprocoumon. |
| Edetic acid | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Edetic acid. |
| Dipyridamole | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Dipyridamole. |
| Heparin | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Heparin. |
| Enoxaparin | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Enoxaparin. |
| Epoprostenol | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Epoprostenol. |
| Acenocoumarol | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Coumarin. |
| Ximelagatran | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Ximelagatran. |
| Desmoteplase | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Desmoteplase. |
| Defibrotide | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Defibrotide. |
| Ancrod | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Ancrod. |
| Beraprost | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Beraprost. |
| SR-123781A | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with SR-123781A. |
| Prasugrel | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Prasugrel. |
| Rivaroxaban | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Rivaroxaban. |
| Sulodexide | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Sulodexide. |
| Semuloparin | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Semuloparin. |
| Idraparinux | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Idraparinux. |
| Cangrelor | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Cangrelor. |
| Astaxanthin | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Astaxanthin. |
| Apixaban | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Apixaban. |
| Otamixaban | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Otamixaban. |
| Amediplase | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Amediplase. |
| Dabigatran etexilate | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Dabigatran etexilate. |
| Danaparoid | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Danaparoid. |
| Dalteparin | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Dalteparin. |
| Tinzaparin | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Tinzaparin. |
| (R)-warfarin | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Ethyl biscoumacetate. |
| Nadroparin | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Nadroparin. |
| Triflusal | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Triflusal. |
| Ticagrelor | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Ticagrelor. |
| Ditazole | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Ditazole. |
| Vorapaxar | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Vorapaxar. |
| Edoxaban | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Edoxaban. |
| Sodium citrate | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Sodium citrate. |
| Dextran | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Dextran. |
| Bemiparin | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Bemiparin. |
| Reviparin | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Reviparin. |
| Parnaparin | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Parnaparin. |
| Desirudin | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Desirudin. |
| Antithrombin Alfa | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Antithrombin Alfa. |
| Protein C | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Protein C. |
| Antithrombin III human | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Antithrombin III human. |
| Letaxaban | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Letaxaban. |
| Darexaban | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Darexaban. |
| Betrixaban | The risk or severity of bleeding can be increased when Betrixaban is combined with Glycol salicylate. |
| Nafamostat | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Nafamostat. |
| Monteplase | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Monteplase. |
| Gabexate | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Gabexate. |
| Troxerutin | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Troxerutin. |
| Fluindione | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Fluindione. |
| Protein S human | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Protein S human. |
| Brinase | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Brinase. |
| Clorindione | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Clorindione. |
| Diphenadione | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Diphenadione. |
| Tioclomarol | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Tioclomarol. |
| Melagatran | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Melagatran. |
| Saruplase | The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Saruplase. |